Correlation Between Foghorn Therapeutics and Virax Biolabs

Can any of the company-specific risk be diversified away by investing in both Foghorn Therapeutics and Virax Biolabs at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Foghorn Therapeutics and Virax Biolabs into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Foghorn Therapeutics and Virax Biolabs Group, you can compare the effects of market volatilities on Foghorn Therapeutics and Virax Biolabs and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Foghorn Therapeutics with a short position of Virax Biolabs. Check out your portfolio center. Please also check ongoing floating volatility patterns of Foghorn Therapeutics and Virax Biolabs.

Diversification Opportunities for Foghorn Therapeutics and Virax Biolabs

0.15

Correlation Coefficient

Foghorn Therapeutics  Virax Biolabs

Average diversification

The 3 months correlation between Foghorn and Virax is 0.15. Overlapping area represents the amount of risk that can be diversified away by holding Foghorn Therapeutics and Virax Biolabs Group in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Virax Biolabs Group and Foghorn Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Foghorn Therapeutics are associated (or correlated) with Virax Biolabs. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Virax Biolabs Group has no effect on the direction of Foghorn Therapeutics i.e., Foghorn Therapeutics and Virax Biolabs go up and down completely randomly.

Pair Corralation between Foghorn Therapeutics and Virax Biolabs

Given the investment horizon of 90 days Foghorn Therapeutics is expected to generate 0.71 times more return on investment than Virax Biolabs. However, Foghorn Therapeutics is 1.4 times less risky than Virax Biolabs. It trades about -0.03 of its potential returns per unit of risk. Virax Biolabs Group is currently generating about -0.09 per unit of risk. If you would invest  461.00  in Foghorn Therapeutics on December 28, 2024 and sell it today you would lose (73.00) from holding Foghorn Therapeutics or give up 15.84% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Foghorn Therapeutics  vs.  Virax Biolabs Group

Foghorn Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Foghorn Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unsteady performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.

Virax Biolabs Group

Risk-Adjusted Performance

Very Weak

Over the last 90 days Virax Biolabs Group has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Foghorn Therapeutics and Virax Biolabs

The main advantage of trading using opposite Foghorn Therapeutics and Virax Biolabs positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Foghorn Therapeutics position performs unexpectedly, Virax Biolabs can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Virax Biolabs will offset losses from the drop in Virax Biolabs' long position.

The idea behind Foghorn Therapeutics and Virax Biolabs Group pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.